Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies. - Wikidata - awgldk - TriplyDB

Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies.

Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies.

http://www.wikidata.org/entity/Q37974461

about

Localization and upregulation of survivin in cancer health disparities: a clinical perspective A potential role of X-linked inhibitor of apoptosis protein in mitochondrial membrane permeabilization and its implication in cancer therapy The isopeptidase inhibitor 2cPE triggers proteotoxic stress and ATM activation in chronic lymphocytic leukemia cells.Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers.Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy.Targeting the inhibitor of Apoptosis Protein BIR3 binding domains.Regulation of antiapoptotic and cytoprotective pathways in colonic epithelial cells in ulcerative colitis.Therapeutic targeting of necroptosis by Smac mimetic bypasses apoptosis resistance in acute myeloid leukemia cells.The SMAC mimetic BV6 induces cell death and sensitizes different cell lines to TNF-α and TRAIL-induced apoptosis.Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment.Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis.Highlights of the third International Conference on Immunotherapy in Pediatric Oncology.XIAP and cIAP1 amplifications induce Beclin 1-dependent autophagy through NFκB activation Baculoviral IAP Repeat Containing 6 (BIRC6) Is a Predictor of Prognosis in Prostate Cancer.

P2860

Q26799719-33141DA6-878C-4757-89E4-93D0721994AB Q36495236-640BCE2A-E22E-4C15-8389-9213FCC5256F Q37564440-7ADCC3A4-B1D0-4E5D-9CAE-AEF68DD3DBF1 Q37580273-9F491060-F36C-4EFD-BA08-740B73AEFFF8 Q38183852-0E85BAC7-7426-4A9B-BA5C-6705506E3F1F Q38226672-970D6673-FD47-4B63-A647-62A0158EBA8E Q38619242-5AAECA4D-8314-49DF-978C-5EE271EB84BE Q38729922-CAAE4A55-8ECB-4C54-9D09-23B58F9140EA Q38755349-9690560B-BDCC-4B91-AA11-A50F30C75EE4 Q38868257-7992B8EC-37EF-430A-91AE-3CBCD3C7EF53 Q39096643-383A3502-0C77-4E4B-8C41-C1C59CB1EE39 Q39403785-4D37A3A1-3F6B-47AA-AF61-5532B059BC49 Q39869165-B1BE537D-337C-45E0-B569-966029E5E777 Q50074531-BFC2EB74-C923-4920-BFE3-49E3930E647C

P2860

Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies.

http://www.wikidata.org/entity/Q37974461

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Exploiting inhibitor of apopto ...... in hematological malignancies.

@en

Exploiting inhibitor of apopto ...... in hematological malignancies.

@nl

type

label

Exploiting inhibitor of apopto ...... in hematological malignancies.

@en

Exploiting inhibitor of apopto ...... in hematological malignancies.

@nl

prefLabel

Exploiting inhibitor of apopto ...... in hematological malignancies.

@en

Exploiting inhibitor of apopto ...... in hematological malignancies.

@nl

P1433

Q37974461-824DBE6F-625A-4CD3-B448-646CDBF09C0E

P1476

Q37974461-92A7AE04-FF41-4FBB-A5F6-AD4E46CE8155

P2860

Q37974461-00AD3561-9D5A-4A61-B7FA-B6C129D97B4C

Q37974461-098CCEB9-A8CA-4F1A-8AAF-8C02EB657F9D

Q37974461-0B231CC3-FDED-4205-9106-D6483DA0632C

Q37974461-103AFD6F-8E82-4EAB-AD38-8B099A36D7A7

Q37974461-13B36517-2A8C-4ABB-8061-45F46F0AD866

Q37974461-13E28BED-9DB3-4FA3-9269-D0D0DCB5E7E5

Q37974461-166E1278-7C78-446A-8120-215BCFA52991

Q37974461-1783C01A-FA98-4C6D-9638-8578186A8147

Q37974461-193E950D-3282-47B1-959D-378E90FC09B7

Q37974461-1C7FC957-622E-485C-9698-D701E39574BA

P2888

Q37974461-36D0576A-0794-4451-ABD8-19499238117D

P304

Q37974461-B067C058-4015-458A-839F-91150D55FC1E

P31

Q37974461-FDF2F709-62FB-4ACA-8CFE-3AD53F308AA4

P356

Q37974461-3A61A007-6919-4F9E-8801-9803881CB9BC

P433

Q37974461-40420F8A-0B46-46D1-9A74-2E3EF722ED8B

P478

Q37974461-3A886EAF-5FCE-44CC-ABA3-EAC866A4CB54

P50

Q37974461-03DAA4D4-5660-4907-A5B3-A6FF6B47B536

P577

Q37974461-1BA0150B-AB10-4B5B-B5A3-68509E3EA962

P698

Q37974461-2FEE13A1-E829-486C-95CB-82C74F4B538E

P356

P1433

P1476

Exploiting inhibitor of apopto ...... in hematological malignancies.

@en

P2860

A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue

Livin, a novel inhibitor of apoptosis protein family member

ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas

Structural basis of caspase-7 inhibition by XIAP

Structural basis for the inhibition of caspase-3 by XIAP

SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP)

Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor α-induced necroptosis

Subcellular localization determines the delicate balance between the anti- and pro-apoptotic activity of Livin

Mechanism of XIAP-mediated inhibition of caspase-9

IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis

P2888

P304

1155-1165

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2012.4

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22230799

http://www.w3.org/2001/XMLSchema#string